Pfizer Research and Development Expenses 2010-2022 | PFE
Pfizer annual/quarterly research and development expenses history and growth rate from 2010 to 2022. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Pfizer research and development expenses for the quarter ending December 31, 2022 were $3.616B, a 4.93% increase year-over-year.
- Pfizer research and development expenses for the twelve months ending December 31, 2022 were $11.428B, a 10.31% increase year-over-year.
- Pfizer annual research and development expenses for 2022 were $11.428B, a 10.31% increase from 2021.
- Pfizer annual research and development expenses for 2021 were $10.36B, a 18.96% increase from 2020.
- Pfizer annual research and development expenses for 2020 were $8.709B, a 3.86% increase from 2019.
Pfizer Annual Research and Development Expenses
(Millions of US $) |
| 2022 |
$11,428 |
| 2021 |
$10,360 |
| 2020 |
$8,709 |
| 2019 |
$8,385 |
| 2018 |
$7,760 |
| 2017 |
$7,683 |
| 2016 |
$7,892 |
| 2015 |
$7,690 |
| 2014 |
$8,393 |
| 2013 |
$6,678 |
| 2012 |
$7,482 |
| 2011 |
$8,681 |
| 2010 |
$9,483 |
| 2009 |
$7,824 |
Pfizer Quarterly Research and Development Expenses
(Millions of US $) |
| 2022-12-31 |
$3,616 |
| 2022-09-30 |
$2,696 |
| 2022-06-30 |
$2,815 |
| 2022-03-31 |
$2,301 |
| 2021-12-31 |
$3,446 |
| 2021-09-30 |
$2,681 |
| 2021-06-30 |
$2,239 |
| 2021-03-31 |
$1,994 |
| 2020-12-31 |
$2,659 |
| 2020-09-30 |
$2,300 |
| 2020-06-30 |
$2,078 |
| 2020-03-31 |
$1,672 |
| 2019-12-31 |
$2,557 |
| 2019-09-30 |
$2,283 |
| 2019-06-30 |
$1,842 |
| 2019-03-31 |
$1,703 |
| 2018-12-31 |
$2,212 |
| 2018-09-30 |
$2,008 |
| 2018-06-30 |
$1,797 |
| 2018-03-31 |
$1,743 |
| 2017-12-31 |
$2,315 |
| 2017-09-30 |
$1,865 |
| 2017-06-30 |
$1,787 |
| 2017-03-31 |
$1,716 |
| 2016-12-31 |
$2,532 |
| 2016-09-30 |
$1,881 |
| 2016-06-30 |
$1,748 |
| 2016-03-31 |
$1,731 |
| 2015-12-31 |
$2,349 |
| 2015-09-30 |
$1,722 |
| 2015-06-30 |
$1,734 |
| 2015-03-31 |
$1,885 |
| 2014-12-31 |
$3,209 |
| 2014-09-30 |
$1,802 |
| 2014-06-30 |
$1,759 |
| 2014-03-31 |
$1,623 |
| 2013-12-31 |
$1,811 |
| 2013-09-30 |
$1,627 |
| 2013-06-30 |
$1,530 |
| 2013-03-31 |
$1,710 |
| 2012-12-31 |
$1,933 |
| 2012-09-30 |
$1,887 |
| 2012-06-30 |
$1,600 |
| 2012-03-31 |
$2,062 |
| 2011-12-31 |
$2,183 |
| 2011-09-30 |
$2,176 |
| 2011-06-30 |
$2,231 |
| 2011-03-31 |
$2,091 |
| 2010-12-31 |
$2,893 |
| 2010-09-30 |
$2,188 |
| 2010-06-30 |
$2,181 |
| 2010-03-31 |
$2,221 |
| 2009-12-31 |
$2,792 |
| 2009-09-30 |
$1,632 |
| 2009-06-30 |
$1,695 |
| 2009-03-31 |
$1,705 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$225.720B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
